Teva Pharmaceutical Industries Limited (TEVA)
Teva Pharmaceutical Industries Limited reported revenue of $17.26B for the fiscal year ended Dec 31, 2025, up 4.3% from $16.54B the year before. Net income was $1.41B, a net margin of 8.2% (prior year: −$1.64B). At the end of that fiscal year the company reported total assets of $40.75B and shareholders' equity of $7.91B.
Revenue
$17.26B
+4.3% vs prior year
Net income
$1.41B
Net margin 8.2%
Diluted EPS
$1.21
USD per share
Total assets
$40.75B
At Dec 31, 2025
Equity
$7.91B
At Dec 31, 2025
Shares outstanding
1,167M
As of Sep 30, 2026
Explore Teva Pharmaceutical Industries Limited's filings
- Revenue by year — annual and quarterly revenue with growth rates
- Income statement & cash flow — profit, margins, EPS and operating cash flow
- Balance sheet — assets, liabilities, equity, cash and debt
- SEC filings — 10-K and 10-Q filings with links to EDGAR
Latest SEC filings
- 10-QFiled Nov 3, 2026
- 10-QFiled Jul 29, 2026
- 10-QFiled Apr 29, 2026
- 10-KFiled Feb 3, 2026
- 10-QFiled Nov 5, 2025
- 10-QFiled Jul 30, 2025
Source: SEC EDGAR XBRL company facts for CIK 818686 (raw data). Most recent filing in this dataset: 10-Q filed Nov 3, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.